Vyome Holdings, Inc. (Nasdaq: HIND) (“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today congratulated its Scientific Co-Founder and Director, Dr. Shiladitya Sengupta, PhD, on his promotion to Professor of Medicine at Harvard Medical School. The academic recognition marks an important milestone in Dr. Sengupta’s distinguished scientific career, spanning biomedical research, nanomedicine, bioengineering, drug delivery, and the translation of scientific discoveries into potential therapeutic applications.
Dr. Sengupta joined the Harvard faculty in 2005, following his doctoral studies at the University of Cambridge and postdoctoral research at the Massachusetts Institute of Technology (MIT). His research has focused on understanding disease mechanisms and developing innovative therapeutic technologies, particularly in oncology, inflammation, and drug delivery. He has authored more than 100 scientific publications, including research published in leading journals such as Nature and Cell, and has received several prestigious recognitions, including the MIT Technology Review TR35 Innovator Award and the Era of Hope Scholar Award from the US Department of Defense.
Dr. Shiladitya Sengupta, Co-Founder and Director of Vyome, commented, “I am deeply honored by this academic recognition. My scientific journey has been driven by a simple question: how can our understanding of biology and disease mechanisms be translated into better therapeutic approaches for patients? Over the years, I have had the opportunity to work with exceptional scientists, clinicians, and students across several disciplines. This appointment is a recognition of that collective scientific journey and the contributions of the many people I have worked with. Co-founding Vyome has been an important part of my efforts to connect fundamental research with patient care. I continue to believe that the greatest opportunities in biotechnology lie at the intersection of strong science, interdisciplinary thinking and a deep understanding of unmet medical needs.”
Venkat Nelabhotla, CEO of Vyome, stated, “Dr. Sengupta’s promotion to Professor at Harvard Medical School is a wonderful recognition of his many years of scientific work and his contributions to translational medicine. I have had the privilege of working closely with him in building Vyome, and what has always impressed me is his ability to connect fundamental science with real problems that patients face. Building an innovative biotechnology company requires much more than good science. This recognition is a matter of great pride for all of us at Vyome. It also reinforces our belief that experienced scientific leadership, combined with disciplined development and execution, is fundamental to building a globally competitive biotechnology company.”
Dr. Sengupta has played an important role in Vyome’s scientific foundation, bringing expertise in disease biology, drug delivery, formulation technologies, and translational research. Vyome’s development strategy emphasizes differentiated therapeutic approaches for conditions where patients have limited treatment options. Its programs include VT-1953, an investigational topical therapy being developed for symptoms associated with malignant fungating wounds, and VT-1908, an investigational topical ophthalmic formulation of mycophenolate being developed as a potential non-steroidal treatment for anterior uveitis.
Vyome has previously reported positive results from an investigator-initiated Phase 2 study of VT-1953 and peer-reviewed preclinical findings supporting continued development of VT-1908.
Dr. Sengupta’s academic achievement is independent of Vyome’s clinical and regulatory programs. His continued involvement as a Co-Founder and Director provides scientific experience and perspective to the company’s long-term innovation strategy.
About Vyome Holdings, Inc.
Vyome is building the world’s premier platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome’s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning, Vyome seeks to deliver lasting value to shareholders in a cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit www.vyometx.com.
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project,” “outlook,” “potential,” “vision,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such statements include, but are not limited to, statements contained in this press release relating to Vyome’s business strategy, including its development strategy and long-term innovation strategy; the continued involvement of Dr. Sengupta with Vyome and the contributions of his scientific experience and perspective; the development plans for VT-1953 and VT-1908; and Vyome’s ability to deliver lasting value to shareholders in a cost-efficient manner. Forward-looking statements are based on Vyome’s current expectations and assumptions regarding Vyome’s business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Vyome’s actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. Vyome cautions you, therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, Vyome’s ability to retain key scientific and management personnel; Vyome’s ability to protect Vyome’s intellectual property rights; the impact of any infringement actions or other litigation brought against Vyome; the timing, cost and outcome of preclinical and clinical development of VT-1953 and VT-1908; Vyome’s ability to obtain regulatory approval for VT-1953, VT-1908 or any other product candidate; the accuracy of Vyome’s market size estimates and assumptions; competition from other providers and products; Vyome’s ability to develop and commercialize products and services; changes in government regulation; Vyome’s ability to complete capital raising transactions and obtain sufficient funding for its development programs; and other factors relating to Vyome’s industry, operations and results of operations, including those discussed under “Risk Factors” in Vyome’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause Vyome’s actual results to differ may emerge from time to time, and it is not possible for Vyome to predict all of them. Vyome cannot guarantee future results, levels of activity, performance, or achievements. Vyome assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release, except as may be required under applicable securities law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261026151753/en/
Media gallery
